Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?-Reference-Cited by-同舟云学术

Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?

Published:2015 Issue:4 Volume:2 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Grard Soazic¹,Catho Gaud²³,Valour Florent³⁴,Bouaziz Anissa³,Perpoint Thomas³,Braun Evelyne³,Biron François³,Miailhes Patrick³,Ferry Tristan³⁴,Chidiac Christian³,Souquet Pierre-Jean¹,Couraud Sébastien¹,Lina Gérard⁵⁴,Goutelle Sylvain⁶,Veziris Nicolas⁷,Dumitrescu Oana⁵⁴,Ader Florence³⁴,Ader F.,Biron F.,Boibieux A.,Bouaziz A.,Bouledrak K.,Braun E.,Catho G.,Chidiac C.,Chumbi-Flores W.,Couraud S.,Devouassoux G.,Dumitrescu O.,Ferry T.,Freymond N.,Gardes S.,Gerbier-Colomban S.,Gillet Y.,Goutelle S.,Grando J.,Grima R.,Hees L.,Jubin V.,Kiakouama-Maleka L.,Lina G.,Maury J.M.,Miailhes P.,Perpoint T.,Perrot Em.,Perrot Emm,Reix P.,Renaud-Baron A.S.,Ronin V.,Senechal A.,Souquet P.J.,Thai Van H.,Tronc F.,Valour F.,Vanhems P.,

Affiliation:

1. Service de Pneumologie et Oncologie Thoracique

2. Service de Pneumologie et Allergologie Pédiatriques, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron

3. Service de Maladies Infectieuses et Tropicales, Hôpital de la Croix-Rousse, Hospices Civils de Lyon

4. Institut National de la Santé et de la Recherche Médicale (INSERM) U1111 Centre International de Recherche en Infectiologie (CIRI), Université Claude Bernard Lyon I

5. Laboratoire de Microbiologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite

6. Unité Mixte de Recherche Centre National de la Recherche Scientifique 5558, Laboratoire de Biométrie et Biologie Évolutive, Villeurbanne

7. Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Laboratoire de Bactériologie-Hygiène, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Sorbonne Universités, Unité de Phytopharmacie et Médiateurs Chimiques University Paris 06, CR7, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Team 13 (Bacteriology), Fra

Abstract

Abstract Linezolid (LNZ), a group 5 antituberculous drug (unclear efficacy), was used in the starter regimens of 23 adults with multidrug-resistant tuberculosis. The LNZ-containing regimens were effective in achieving culture conversions and relapse-free outcomes. The most frequent LNZ-related side effect was neuropathy. We propose that LNZ should be reclassified among bactericidal second-line drugs.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/article-pdf/2/4/ofv175/33603902/ofv175.pdf

Reference25 articles.

1. A surge of MDR and XDR tuberculosis in France among patients born in the former Soviet Union;Bernard;Euro Surveill,2013

2. Worldwide emergence of extensively drug-resistant tuberculosis;Shah;Emerg Infect Dis,2007

3. Resistance patterns of multidrug-resistant tuberculosis in Western Province, Papua New Guinea;Simpson;Int J Tuberc Lung Dis,2011

4. Drug resistance in tuberculosis;Mitchison;Eur Respir J,2005

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ensemble-based high-throughput virtual screening of natural ligands using the Super Natural-II database against cell-wall protein dTDP-4-dehydrorhamnose reductase (RmlD) in Mycobacterium tuberculosis;Journal of Biomolecular Structure and Dynamics;2020-12-31

2. A review of recent advances in anti-tubercular drug development;Indian Journal of Tuberculosis;2020-10

3. Linezolid for drug-resistant pulmonary tuberculosis;Cochrane Database of Systematic Reviews;2019-03-20

4. Antituberculous drugs modulate bacterial phagolysosome avoidance and autophagy in Mycobacterium tuberculosis-infected macrophages;Tuberculosis;2018-07